Nanobiotix (NBTX) Cash & Equivalents (2018 - 2025)

Nanobiotix (NBTX) has 8 years of Cash & Equivalents data on file, last reported at $61.5 million in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 15.64% year-over-year to $61.5 million; the TTM figure through Dec 2025 stood at $61.5 million (up 15.64% YoY), while the FY2025 annual figure was $59.7 million, up 10.81% from the prior year.
• Cash & Equivalents advanced to $61.5 million in Q4 2025, from $53.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $96.0 million in Q4 2021 and bottomed at $42.2 million in Q4 2022.
• A 5-year average of $66.8 million and a median of $61.5 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 56.02% — and 2023, when it surged 91.82%.
• Year by year, Cash & Equivalents stood at $96.0 million in 2021, then tumbled by 56.02% to $42.2 million in 2022, then surged by 91.82% to $81.0 million in 2023, then slumped by 34.38% to $53.1 million in 2024, then rose by 15.64% to $61.5 million in 2025.
• The last three Cash & Equivalents figures came in at $61.5 million (Q4 2025), $53.1 million (Q4 2024), and $81.0 million (Q4 2023), per Business Quant data.

Peer Comparison